Carbapenem antibiotic with beta-lactamase inhibitor

This page covers all Carbapenem antibiotic with beta-lactamase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Penicillin-binding proteins (PBPs); beta-lactamase inhibition, Bacterial penicillin-binding proteins; serine beta-lactamases.

Targets

Penicillin-binding proteins (PBPs); beta-lactamase inhibition · Bacterial penicillin-binding proteins; serine beta-lactamases

Marketed (2)

• Imipenem, Cilastatin and Relebactam · Joseph L. Kuti, PharmD · Infectious Disease
  Imipenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, cilastatin protects imipenem from renal degradation, and relebactam is a beta-lactamase inhibitor that prevents bacterial resistance.
• Imipenem/Cilastatin/Relebactam · Evopoint Biosciences Inc. · Infectious Disease
  Imipenem/cilastatin/relebactam is a combination of a broad-spectrum beta-lactam antibiotic, a renal dehydropeptidase inhibitor, and a beta-lactamase inhibitor that together kill bacteria by inhibiting cell wall synthesis while protecting against enzymatic degradation.

Patent intelligence

• carbapenem antibiotic with beta lactamase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates